UPL is currently trading at Rs. 579.40, up by 29.15 points or 5.30% from its previous closing of Rs. 550.25 on the BSE.
The scrip opened at Rs. 571.00 and has touched a high and low of Rs. 593.00 and Rs. 560.25 respectively. So far 189984 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 902.00 on 01-Aug-2017 and a 52 week low of Rs. 537.90 on 19-Jul-2018.
Last one week high and low of the scrip stood at Rs. 593.00 and Rs. 537.90 respectively. The current market cap of the company is Rs. 29312.12 crore.
The promoters holding in the company stood at 27.75%, while Institutions and Non-Institutions held 50.20% and 13.78 % respectively.
UPL’s wholly owned subsidiary -- UPL Corporation (UPL Corp) Mauritius -- has signed a definitive agreement with Platform Specialty Products Corporation to acquire Arysta LifeScience Inc. and its subsidiaries (collectively 'Arysta'), a global provider of innovative crop protection solutions, including BioSolutions and Seed Treatment, for around $4.2 billion in cash consideration, subject to customary closing conditions and regulatory approvals.
The Board of Directors of the company has approved this acquisition in its meeting held on July 20, 2018.
UPL is global player of crop protection products has customer base in 123 countries. It has subsidiary offices in Argentina, Australia, Bangladesh, Brazil, China, Canada, Denmark, Indonesia, France, Hong Kong, Japan, Korea, Mauritius, Mexico, New Zealand, Russia, Spain, Taiwan, South Africa, USA, UK, Vietnam and Zambia.
| Company Name | CMP |
|---|---|
| UPL | 665.95 |
| PI Industries | 3099.70 |
| Bayer CropScience | 4852.00 |
| Sharda Cropchem | 1126.75 |
| Sumitomo Chemical | 434.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: